Forbes Health has ranked the best providers for pricing, patient care, effectiveness and ease of use. This way you can cut through the scams and noise to make an informed decision when choosing an ...

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Because of the challenges associated with many ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one ...

Get the skinny on getting skinny. — -- Just in time for swimsuit season, a new study has come out saying there's very little scientific evidence to prove most diet and weight-loss regimens ...

As glucagon-like peptide-1 receptor agonists like Ozempic and Mounjaro surge in popularity and influence economies around the world, health systems are magnifying their weight management programs.

In the first head-to-head comparison of two blockbuster drugs used in real-world conditions, people who took Mounjaro lost significantly more weight than their counterparts who took Ozempic — and the ...

For those who thought Ozempic would spell the end of diet programs, think again. WeightWatchers this week launched WeightWatchers GLP-1, a subscription program focused on the health and nutrition ...

The Danish company is trying to regain market share from Eli Lilly — which makes Mounjaro and Zepbound — by making its weight ...

Direct-to-consumer telemedicine platform Hims & Hers launched a new weight loss program Monday that offers weight loss medications, educational content and digital tracking tools. San Francisco-based ...

A daily oral GLP-1 pill can help people with obesity lose about 12% of their body weight, according to early data shared by drugmaker Eli Lilly today. The medication, called orforglipron, may be a ...

Shares of biotechnology companies like Viking Therapeutics (NASDAQ: VKTX) have exploded upward by over 300% in the last 12 months, thanks to its phenomenal clinical data from its late-stage weight ...